---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028283"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:36:17.944914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor

## Summary
- CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
- No serious adverse events, severe TEAEs, or clinically significant lab/ECG findings; all 48 participants completed.
- CDI-988 targets a conserved 3CL protease region; potential first dual broad-spectrum treatment for norovirus and coronavirus.
- MAD cohort enrollment planned to start in Q4 2024; drug product currently being manufactured.
- Norovirus causes ~21M US cases/year; no approved antiviral or vaccine for norovirus.

## SEC filing metadata
- accession: 0001493152-24-028283
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224028283/0001493152-24-028283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224028283/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028283
- JSON: https://secwatch.observer/filing/0001493152-24-028283.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.